Broad Institute, Collaborators Eye CRISPR Panel to Detect SARS-CoV-2 Variants, Respiratory Viruses
The group has developed a panel to detect SARS-CoV-2, other coronaviruses, and influenza A and B that also identified and differentiated six variant lineages.
Fluidigm Q4 Revenues Down 14 Percent as COVID-19 Testing Revenue Declines
The firm posted revenues of $38.3 million compared to $44.6 million a year ago as a decline in COVID-19 testing offset a recovery in its base business.
Fluidigm, Uh-Oh Labs Get Emergency Use Authorization for COVID-19 Tests
Both companies had previously received funding to develop COVID-19 tests from the National Institutes of Health's Rapid Acceleration of Diagnostics initiative.
In Brief This Week: Cepheid, Biocartis, Sight Diagnostics, Fluidigm, Co-Diagnostics, and More
News items for in vitro diagnostics industry for the week of Jan. 10, 2022.
Danaher, PerkinElmer, Cue Health, Others Announce Preliminary Q4 Earnings Results
Other companies reporting preliminary Q4 financial results included Fluidigm, SomaLogic, and T2 Biosystems.
Aug 5, 2021
Fluidigm Q2 Revenues Grow 19 Percent
May 6, 2021
Fluidigm Q1 Revenues Grow 19 Percent
Feb 11, 2021